About us Contacts Drug interactions: 390 212
Drug search by name

Raltegravir Chewable Tablets and Rifadin

Determining the interaction of Raltegravir Chewable Tablets and Rifadin and the possibility of their joint administration.

Check result:
Raltegravir Chewable Tablets <> Rifadin
Relevance: 19.06.2022 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Talk to your doctor before using raltegravir together with rifAMPin. Combining these medications can decrease the blood levels of raltegravir, which may reduce its effectiveness in treating HIV infection. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Professional:

ADJUST DOSE: Coadministration with rifampin may significantly decrease the plasma concentrations of raltegravir. The proposed mechanism is rifampin induction of raltegravir metabolism via uridine diphosphate glucuronosyltransferase (UGT) 1A1. In 9 study subjects, administration of a single 400 mg dose of raltegravir in combination with rifampin 600 mg daily resulted in a 38% decrease in raltegravir peak plasma concentration (Cmax), a 40% decrease in systemic exposure (AUC), and a 61% decrease in trough plasma concentration (Cmin) compared to administration of raltegravir alone. When the dosage of raltegravir was increased to 800 mg twice daily and coadministered with rifampin 600 mg daily in 14 subjects, raltegravir Cmax and AUC increased by 62% and 27%, respectively, while Cmin decreased by 53% compared to administration of raltegravir alone at 400 mg twice daily.

MANAGEMENT: Caution is advised when raltegravir must be used in combination with rifampin. A dosage increase for raltegravir to 800 mg twice daily is recommended for adults during coadministration with rifampin. No dosage adjustment recommendations are available for pediatric patients below 18 years of age due to the lack of clinical data.

References
  • Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."
  • Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  • "Product Information. Isentress (raltegravir)." Merck & Company Inc, West Point, PA.
Raltegravir Chewable Tablets

Generic Name: raltegravir

Brand name: Isentress, Isentress HD

Synonyms: Raltegravir

Rifadin

Generic Name: rifampin

Brand name: Rifadin, Rifadin IV, Rimactane

Synonyms: n.a.

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.

Interaction with food and lifestyle